Five things you should know about Micropulse LASER in Glaucoma Management
Glaucoma is a leading cause of irreversible blindness worldwide, with more than 70 million people affected. Traditionally treatment options include topical medications, laser trabeculoplasty, incisional surgeries, glaucoma drainage implants (GDD), and cycloablative procedures. GDD and ciliary body destruction is generally reserved for refractory or end-stage glaucoma in eyes with poor visual potential. Transscleral cyclophotocoagulation (TSCPC) Transscleral cyclophotocoagulation (TSCPC) is a cyclodestructive procedure designed to target the melanin in the pigmented ciliary body epithelium, thereby decreasing the rate of aqueous humor production. Numerous studies have confirmed the IOP-lowering ability of TSCPC and also reported the risk of developing serious complications with this procedure, such as persistent ocular inflammation, vision loss, hypotony, phthisis bulbi, and rarely sympathetic ophthalmia. Therefore, TSCPC, which conventionally uses the continuous-wave diode laser, has b

